What happens next in GLP-1 — and when.

Get the briefing

What moved in the GLP‑1 field, in your inbox.

@glp1briefing

Indications › Diabetes (unspecified) › exenatide

exenatide in diabetes (unspecified)

exenatide is not approved in the US for diabetes (unspecified), and has 14 trials on file here in this condition. 9 of them are phase 3 or later. No trial here has a completion date still in the future, so this is a closed body of work rather than an active programme. Being studied in a condition is not the same as being approved for it; most such programmes end without an approval.

14 registered trials study exenatide (Bydureon, Byetta) in diabetes (unspecified). None has a scheduled reporting date on file.

Trials on file
14
Active
0
Active phase 3
0
Participants in active trials
0
Sponsors
10
Scheduled readouts
0

All trials on file

Every registered trial of exenatide grouped under diabetes (unspecified), largest first. Grouping follows the registry’s own condition wording.

TrialStatusPhaseSponsor
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
NCT02229396
CompletedP3AstraZeneca
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
NCT02229383
CompletedP3AstraZeneca
Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.
NCT00313001
CompletedP3Novo Nordisk A/S
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
NCT01107717
CompletedP4The University of Texas Health Science Center at San Antonio
Safety and Efficacy of YH14617 in Diabetes Mellitus
NCT01507038
CompletedP2Yuhan Corporation
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
NCT00701935
TerminatedP2AstraZeneca
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
NCT01452451
CompletedP2Hanmi Pharmaceutical Company Limited
Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes
NCT00064714
CompletedP2AstraZeneca
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics
NCT02042664
CompletedP3Assistance Publique Hopitaux De Marseille
Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects
NCT02621489
CompletedP4Karolinska Institutet
A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass
NCT04615910
UnknownP2Radboud University Medical Center
Acute Effect of Exenatide on Brain Glucose Metabolism
NCT01588418
CompletedP4The University of Texas Health Science Center at San Antonio
Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults
NCT01791465
TerminatedP4Vanderbilt University
A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects
NCT02802514
TerminatedP4GlaxoSmithKline

See the full record for exenatide, or every molecule being studied in diabetes (unspecified). These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.